Roderick Verhelst

Principal

2022 - Current

Principal Life Sciences & Care

2021 - 2022

Senior Investment Manager Life Sciences & Care

2019 - 2021

• As a Senior investment manager I'm responsible for the complete investment track, from deal-sourcing to closing. • In addition I'm a board member in several healthcare companies that are at various stages of maturity (GST, Bluebee, miDIAGNOSTICS & Flamingo Therapeutics)

Investment Manager Life Sciences & Care

2016 - 2019

• Evolved from a "shadow role" to leading the transaction from deal sourcing to closing. • Successfully closed GST and Bluebee.

Board Member

2020 - 2022

Board Member

2019 - 2022

miDiagnostics is developing breakthrough technology for rapid, high-quality and inexpensive diagnostic testing to address medical questions without the need to rely on a complex laboratory infrastructure. Its core technology is based on a silicon chip that executes different operations at the microscale, similar to a microprocessor inside a smartphone. But instead of dealing with electrons, miDiagnostics precisely controls fluids inside its silicon chip without the need for external fluid actuation. This allows to accurately detect cells, proteins, nucleic acids (DNA/RNA), and small molecules.

Board Observer

2020 - 2021

Genomics data analysis platform configured for providers of molecular assays or high-throughput services. Integrated data analysis, data management, and data science software solutions, from raw data to report and beyond.

Board Member

2020 - 2021

Board Member

2020 - 2021

Confo Therapeutics employs its proprietary CONFO® technology to lock inherently unstable functional conformations of GPCRs as a superior starting point for drug discovery. Confobody-stabilized active state conformations of these receptors reveal previously inaccessible structural features empowering the discovery of novel pathway-selective agonists for improved therapeutic intervention.​

Board Member

2018 - 2019

Global Stem cell Technology (GST) NV is a veterinary biotech company which was founded in 2012 to develop and produce state-of-the art stem cell products for horses and dogs. The company launched the first EMA approved veterinary stem cell product. The latter product is partnered with Boehringer Ingelheim. https://www.boehringer-ingelheim.com/press-release/boehringer-ingelheim-and-gst-prepared-bring-innovation-equine-market

Sell-side analyst Healthcare

2012 - 2016

•Responsible for coverage of BeNeLux healthcare sector, ranging from day-to-day news flow to in-depth research reports •Companies under coverage: Ablynx, arGEN-X, Biocartis, Celyad, Curetis, Fagron, Galapagos, Probiodrug, IBA, Tigenix, MDxHealth, Thrombogenics, UCB Skills: •Valuation of healthcare companies (DCF, peer analysis…) •Strong financial modelling skills •Highly developed writing and presentation skills •Commercial mind-set Achievements •Successfully completed several high-profile BeNeLux IPOs (arGEN-X, Biocartis, Curetis and Probiodrug) and ABBs (Celyad, Fagron and MDxHealth), >EUR 500m was raised during these operations •More than quadrupled day-to-day commissions in 36 months’ time

PHD Student

2007 - 2011

PhD Bioscience Engineering (KU Leuven) September 2007- September 2011: “Discovery and evaluation of new feed components for the inhibition of enterotoxigenic Escherichia coli” Skills: •Practical know-how of various laboratory techniques (PCR, antibody-production, ELISA…) •Extensive knowledge in the field of immunology/microbiology Achievements: •Published research in high ranking peer-reviewed journals •Speaker at international conferences